| pubmed-article:1515256 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1515256 | lifeskim:mentions | umls-concept:C0194037 | lld:lifeskim |
| pubmed-article:1515256 | lifeskim:mentions | umls-concept:C0855082 | lld:lifeskim |
| pubmed-article:1515256 | lifeskim:mentions | umls-concept:C1328050 | lld:lifeskim |
| pubmed-article:1515256 | pubmed:issue | 8-9 | lld:pubmed |
| pubmed-article:1515256 | pubmed:dateCreated | 1992-10-8 | lld:pubmed |
| pubmed-article:1515256 | pubmed:abstractText | The results of high-dose chemotherapy with melphalan or melphalan (carmustine) etoposide for 66 consecutive patients with relapsed or resistant Hodgkin's disease are described. 55 patients were evaluable for response and 22% of these achieved complete remission and 59% partial remission. The actuarial survival at 2 years was 45% and the principal factors determining survival were the sensitivity of the disease to therapy given before high-dose chemotherapy and the type of treatment received. Intensive chemotherapy with autologous bone marrow transplantation can produce long-term survivors among patients for whom long-term survival would otherwise be improbable. However, this treatment remains toxic with an uncertain place in management. | lld:pubmed |
| pubmed-article:1515256 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1515256 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1515256 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1515256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1515256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1515256 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1515256 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1515256 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:1515256 | pubmed:author | pubmed-author:GoreMM | lld:pubmed |
| pubmed-article:1515256 | pubmed:author | pubmed-author:HardingMM | lld:pubmed |
| pubmed-article:1515256 | pubmed:author | pubmed-author:SelbyPP | lld:pubmed |
| pubmed-article:1515256 | pubmed:author | pubmed-author:MansiJJ | lld:pubmed |
| pubmed-article:1515256 | pubmed:author | pubmed-author:PerrenTT | lld:pubmed |
| pubmed-article:1515256 | pubmed:author | pubmed-author:VinetAA | lld:pubmed |
| pubmed-article:1515256 | pubmed:author | pubmed-author:MilanSS | lld:pubmed |
| pubmed-article:1515256 | pubmed:author | pubmed-author:MeldrumMM | lld:pubmed |
| pubmed-article:1515256 | pubmed:author | pubmed-author:ZulianGG | lld:pubmed |
| pubmed-article:1515256 | pubmed:author | pubmed-author:TreleavanJJ | lld:pubmed |
| pubmed-article:1515256 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1515256 | pubmed:volume | 28A | lld:pubmed |
| pubmed-article:1515256 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1515256 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1515256 | pubmed:pagination | 1396-400 | lld:pubmed |
| pubmed-article:1515256 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:meshHeading | pubmed-meshheading:1515256-... | lld:pubmed |
| pubmed-article:1515256 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1515256 | pubmed:articleTitle | High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease. | lld:pubmed |
| pubmed-article:1515256 | pubmed:affiliation | Yorkshire Cancer Research Campaign, Institute for Cancer Studies, St. James's University Hospital, U.K. | lld:pubmed |
| pubmed-article:1515256 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1515256 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1515256 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1515256 | lld:pubmed |
